A study of prognosis and outcome of COVID-19-infected hypertensive patients on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers
Background and Objective: COVID-19 is a pandemic caused by the virus severe acute respiratory syndrome coronavirus-2. The mortality in susceptible populations with chronic pulmonary disease, cardiac ailments, kidney disease, diabetes, and hypertension is high. While the role of angiotensin-convertin...
Main Authors: | M S Bharath, S Ravitej, Vandana Balgi, M C. Rakesh Raje Urs, C S Apoorva |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2024-01-01
|
Series: | APIK Journal of Internal Medicine |
Subjects: | |
Online Access: | http://www.ajim.in/article.asp?issn=2666-1802;year=2024;volume=12;issue=1;spage=51;epage=54;aulast=Bharath |
Similar Items
-
Is there a difference between an angiotensin-converting enzyme inhibitor and an angiotensin-specific receptor blocker for the treatment of hypertension?
by: James A. Ker
Published: (2015-05-01) -
Association of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID‐19
by: Rohan Khera, et al.
Published: (2021-07-01) -
The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy
by: Tao Liu, et al.
Published: (2023-01-01) -
Relating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID‐19
by: Martin C.S. Wong, et al.
Published: (2020-10-01) -
Hyponatremia Induced by Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers-A Pilot Study
by: S Bhuvaneshwari, et al.
Published: (2018-07-01)